Filtered By:
Cancer: Breast Cancer
Drug: Herceptin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1483 results found since Jan 2013.
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival
CONCLUSION: The pCR rate and its prognostic value varied across BC subtypes. In our study, pCR could be used as a surrogate of favorable clinical outcome, as it was associated with higher OS and DFS rates.PMID:37722319 | DOI:10.1016/j.breast.2023.103577
Source: Breast - September 18, 2023 Category: Cancer & Oncology Authors: Marcelo Antonini Andr é Mattar Fernanda Grace Bauk Richter Gabriel Duque Pannain Marina Di ógenes Teixeira Andressa Gon çalves Amorim Odair Ferraro Reginaldo Coelho Guedes Lopes Luiz Henrique Gebrim Juliana Monte Real Source Type: research
HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer
Cancer Res Commun. 2023 Sep 11. doi: 10.1158/2767-9764.CRC-23-0302. Online ahead of print.ABSTRACTThe oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability of HER2-targeted treatments, patients' disease often progresses during therapy, underscoring the need for novel treatment strategies. The addition of tucatinib, a reversible, highly selective HER2 tyrosine kinase inhibitor (TKI), to treatment with trastuzumab and capecitabine significantly improved survival outcomes of patients with HER2-positive metastatic breast cancer, including those with active bra...
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Devra Olson Janelle Taylor Kelsi Willis Kelly Hensley Sean Allred Margo Zaval Lauren Farr Robert Thurman Nishi Jain Renee Hein Michelle Ulrich Scott Peterson Anita Kulukian Source Type: research
Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival
CONCLUSION: The pCR rate and its prognostic value varied across BC subtypes. In our study, pCR could be used as a surrogate of favorable clinical outcome, as it was associated with higher OS and DFS rates.PMID:37722319 | DOI:10.1016/j.breast.2023.103577
Source: Breast - September 18, 2023 Category: Cancer & Oncology Authors: Marcelo Antonini Andr é Mattar Fernanda Grace Bauk Richter Gabriel Duque Pannain Marina Di ógenes Teixeira Andressa Gon çalves Amorim Odair Ferraro Reginaldo Coelho Guedes Lopes Luiz Henrique Gebrim Juliana Monte Real Source Type: research
Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer
CONCLUSIONS: Subspecialised breast pathologists have suboptimal agreement for immunohistochemical evaluation of HLBC using the modified Ki-67 methodology. An urgent need remains for a new assay/algorithm to reliably evaluate HLBC.PMID:37714693 | DOI:10.1136/jcp-2023-209055
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Gulisa Turashvili Yuan Gao Di Andy Ai Abdulwahab M Ewaz Sandra Gjorgova Gjeorgjievski Qun Wang Thi T A Nguyen Chao Zhang Xiaoxian Li Source Type: research
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials
Am J Cancer Res. 2023 Aug 15;13(8):3266-3274. eCollection 2023.ABSTRACTTrastuzumab deruxtecan (T-DXd, DS-8201) is a targeted antibody-drug conjugate that specifically targets human epidermal growth factor receptor 2 (HER2). In 2019, it was approved by the US Food and Drug Administration for the treatment of HER2-positive breast cancer. However, ongoing research is exploring its potential efficacy in other solid tumors, such as non-small-cell lung cancer and colorectal cancer, as well as in tumors with low HER2 levels. It is important to examine the safety and effectiveness of trastuzumab deruxtecan in these various types o...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Ze-Lin Cai Hui-Ting Yang Ting Huang Zhuo-Ran Yu Ning Ren Jing-Yang Su Xian-Lei Lin He-Ran Zhou Source Type: research
The potential of trastuzumab deruxtecan as a tissue agnostic drug
Oncology. 2023 Aug 31. doi: 10.1159/000533866. Online ahead of print.ABSTRACTBACKGROUND: Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue agnostic drug refers to a drug that targets a specific molecular alteration across multiple cancer types, as defined by organ, tissue, or tumor type.SUMMARY: Over the last six years,...
Source: Oncology - August 31, 2023 Category: Cancer & Oncology Authors: Jan Tr øst Jørgensen Source Type: research
